Madrigal Pharmaceuticals Inc [MDGL] stock is trading at $340.14, up 4.75%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The MDGL shares have gain 23.95% over the last week, with a monthly amount glided 15.93%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Wolfe Research started tracking the stock with Outperform rating on June 11, 2024, and set its price target to $382. On April 22, 2024, BofA Securities initiated with a Underperform rating and assigned a price target of $150 on the stock. B. Riley Securities upgraded its rating to a Neutral and increased its price target to $270 on March 15, 2024. Citigroup initiated its recommendation with a Buy and recommended $382 as its price target on March 06, 2024. B. Riley Securities downgraded its rating to Sell for this stock on February 26, 2024, but kept the price target unchanged to $155. In a note dated December 20, 2022, Oppenheimer reiterated an Outperform rating on this stock and boosted its target price from $170 to $250.
Madrigal Pharmaceuticals Inc [MDGL] stock has fluctuated between $168.25 and $368.29 over the past year. Currently, Wall Street analysts expect the stock to reach $315.75 within the next 12 months. Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] shares were valued at $340.14 at the most recent close of the market. An investor can expect a potential drop of -7.17% based on the average MDGL price forecast.
Analyzing the MDGL fundamentals
Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -7.06%, Pretax Profit Margin comes in at -6.69%, and Net Profit Margin reading is -6.69%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.72 and Total Capital is -0.61. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 320.56 points at the first support level, and at 300.98 for the second support level. However, for the 1st resistance point, the stock is sitting at 352.88, and for the 2nd resistance point, it is at 365.62.
Ratios To Look Out For
For context, Madrigal Pharmaceuticals Inc’s Current Ratio is 5.98. In addition, the Quick Ratio stands at 5.93 and the Cash Ratio stands at 1.31. Considering the valuation of this stock, the price to sales ratio is 96.58, the price to book ratio is 9.54.
Transactions by insiders
Recent insider trading involved Kelley Shannon T, General Counsel, that happened on Jan 17 ’25 when 277.0 shares were sold. Senior VP, Chief Pharma Dev., Waltermire Robert E. completed a deal on Jan 17 ’25 to sell 442.0 shares. Meanwhile, Pres., R&D, and CMO Taub Rebecca sold 1689.0 shares on Jan 17 ’25.
